Studies regarding their use in COVID-19 patients showed that inhibition of Gal-3 could modulate the host immune response and reduce cytokine storm syndrome, a major cause of death in COVID-19, alongside preventing viral entry and reducing post-COVID-19 pulmonary fibrosis (44, 45). The gene discussed is LGALS3; the disease is pulmonary fibrosis.